---
figid: PMC2658537__6604891f1
figlink: /pmc/articles/PMC2658537/figure/fig1/
number: F1
caption: Sample signalling scheme showing pathways known to be active in melanoma.
  Preclinical studies support the combined targeting of either BRAF/MAPK and PI3K/AKT
  pathway or the BRAF/MAPK and mTOR signalling pathways in melanoma. It is likely
  that the combined inhibition of BRAF/PI3K pathways will have synergistic effects
  at the level of growth inhibition, via effects upon cyclin D1 expression, as well
  as through increased expression of the cyclin dependent kinase inhibitor p21waf-1/cip-1.
  Inhibition of the AKT/mTOR pathway is likely to affect cell survival via modulation
  of BAD/Bcl-2, as well as affecting protein translation at the level of S-6-kinase
  (S6K).
pmcid: PMC2658537
papertitle: Integrating BRAF/MEK inhibitors into combination therapy for melanoma.
reftext: K S M Smalley, et al. Br J Cancer. 2009 Feb 10;100(3):431-435.
pmc_ranked_result_index: '44111'
pathway_score: 0.9429171
filename: 6604891f1.jpg
figtitle: Sample signalling scheme showing pathways known to be active in melanoma
year: '2009'
organisms: Homo sapiens
ndex: 5587f209-df03-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2658537__6604891f1.html
  '@type': Dataset
  description: Sample signalling scheme showing pathways known to be active in melanoma.
    Preclinical studies support the combined targeting of either BRAF/MAPK and PI3K/AKT
    pathway or the BRAF/MAPK and mTOR signalling pathways in melanoma. It is likely
    that the combined inhibition of BRAF/PI3K pathways will have synergistic effects
    at the level of growth inhibition, via effects upon cyclin D1 expression, as well
    as through increased expression of the cyclin dependent kinase inhibitor p21waf-1/cip-1.
    Inhibition of the AKT/mTOR pathway is likely to affect cell survival via modulation
    of BAD/Bcl-2, as well as affecting protein translation at the level of S-6-kinase
    (S6K).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK3
  - ETS1
  - MAPKAP1
  - MLST8
  - BRAF
  - TSC1
  - MTOR
  - AKT2
  - MAPK1
  - RICTOR
  - RPTOR
  - BAD
  - NRAS
  - PIK3R5
  - MAP2K1
  - TSC2
  - PIK3CB
  - AKT3
  - AKT1
  - PIK3CG
  - PIK3R3
  - PTEN
  - PIK3R6
  - KRAS
  - HRAS
  - PIK3R4
  - MAP2K2
  - PIK3CA
  - PIK3CD
  - tyrosine
  - Cancer
  - Lung cancer
genes:
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ETS-1
  symbol: ETS-1
  source: hgnc_alias_symbol
  hgnc_symbol: ETS1
  entrez: '2113'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MAPKAP1
  entrez: '79109'
- word: GbL
  symbol: GbetaL
  source: hgnc_alias_symbol
  hgnc_symbol: MLST8
  entrez: '64223'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: TSC1
  symbol: TSC1
  source: hgnc_symbol
  hgnc_symbol: TSC1
  entrez: '7248'
- word: (MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: RICTOR
  entrez: '253260'
- word: Raptor
  symbol: raptor
  source: hgnc_alias_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: BAD
  symbol: BAD
  source: hgnc_symbol
  hgnc_symbol: BAD
  entrez: '572'
- word: MTORC2
  symbol: mTORC2
  source: bioentities_symbol
  hgnc_symbol: MLST8
  entrez: '64223'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: (TSC2)
  symbol: TSC2
  source: hgnc_symbol
  hgnc_symbol: TSC2
  entrez: '7249'
- word: sin1
  symbol: SIN1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPKAP1
  entrez: '79109'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: Rictor
  symbol: RICTOR
  source: hgnc_symbol
  hgnc_symbol: RICTOR
  entrez: '253260'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
chemicals:
- word: tyrosine
  source: MESH
  identifier: D014443
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
figid_alias: PMC2658537__F1
redirect_from: /figures/PMC2658537__F1
figtype: Figure
---
